New research reveals that combining lurbinectedin with atezolizumab significantly improves survival rates for patients with ...

In recognition of its innovation, client-focused delivery, and global impact, Novotech has been awarded the 2025 Global Biotechnology Contract Research Organization (CRO) Company of the Year by Frost ...

Organon is terminating development of its endometriosis drug after the Phase II trial failed to show any benefit. The ELENA proof-of-concept study (NCT05560646) was evaluating Organon’s therapy, ...

After decades of setbacks, Alzheimer’s drug development is expanding beyond anti-amyloids, with a record number of trials and ...

Recognized for its biotech-first focus, innovation in clinical trial delivery, and best-in-class client experience, Novotech ...

The GCAptAIN study did not meet its primary endpoint of sustained remission at Week 52 in adults with newly diagnosed or relapsing GCA1 ...

The analysis reveals a strong dominance of AI applications in oncology, comprising 72.8% of all included studies. This skew ...

While biopharmaceutical technologies have made substantial strides in treating diseases, drug research and development ...

Read highlights things to do, places to go and people to know in the Greater Lowell area. Have news to share? Send it to news ...

Sigvotatug Vedotin is an ADC that targets integrin αvβ6-positive tumor cells. It has an engineered antibody that ensures high ...

Automation and artificial intelligence are streamlining everything from regulatory tasks to clinical trials and drug ...

Thermo Fisher Scientific’s Accelerator™ Drug Development solutions, which integrate services for contract development and manufacturing organizations (CDMOs) and contract research organizations (CROs) ...